Format

Send to

Choose Destination
See comment in PubMed Commons below
Cancer Manag Res. 2012;4:243-52. doi: 10.2147/CMAR.S25284. Epub 2012 Aug 8.

Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanoma.

Author information

1
Department of Medical Oncology, Royal Marsden Hospital, London, United Kingdom.

Abstract

The BRAF inhibitor, vemurafenib, has demonstrated improved progression-free and overall survival compared with chemotherapy in a randomized trial, and represents a new standard of care in patients with advanced melanoma harboring a BRAF-V600 mutation. A BRAF-V600 mutation is identified in approximately half of patients with cutaneous melanoma, and is unequivocally a biomarker predictive of profound clinical benefit for these patients. However, acquired vemurafenib resistance is a major clinical challenge and therapy is not yet curative. A substantial body of translational research has been performed alongside clinical trials of vemurafenib, providing key insights into the molecular basis of response and resistance. This review summarizes the development of vemurafenib for the treatment of BRAF-V600 mutant melanoma and discusses how knowledge of critical signaling pathways will be applied for its optimal clinical use in future.

KEYWORDS:

BRAF-V600; BRIM-3; melanoma; vemurafenib

PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Dove Medical Press Icon for PubMed Central
    Loading ...
    Support Center